

Immunodermatology Serum Test Report Navigation Guide

The Immunodermatology TESTING REPORT from the University of Utah follows "See Note" and is arranged as outlined below on the following pages:

CLINICAL INFORMATION This content is provided by the ordering clinician and includes the reason for testing.

Specimen Details This includes specimen identification with collected and received dates.

DIAGNOSTIC INTERPRETATION This is a synopsis of key findings from the testing and their diagnostic relevance.

RESULTS This section reports the discrete finding and value of each test component, along with the reference range.

COMMENTS

Specific

These comments provide an explanation of the test results as they relate to clinical considerations, and include reference to any concurrent and/or previous testing.

General


These comments summarize fundamental information about the test(s) and the component(s) assessed to aid in interpretation of their clinical applicability.

TESTING METHODS The section lists the procedures performed, the test source(s), and the applicable laboratory developed test disclaimer(s).

TEST RESULTS SUMMARY CHART A chart tabulating results of tests ordered for the patient by the same client is included if previous and/or concurrent testing has been performed.

```
ELISA RESULTS GRAPH
A graph of ELISA results also is included if previous and/or
concurrent testing has been performed; the graph may be found on a
subsequent page.
```

For testing algorithm and additional information, refer to: arupconsult.com/content/immunobullous-skin-diseases-screening



Patient: ARUP Accession: 24-079-103960

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director

Chart continues on following page(s) ARUP Enhanced Reporting | March 22, 2024 | page 1 of 9



Department of Dermatology Immunodermatology Laboratory

Immunodermatology.uofumedicine.org

John J. Zone, MD - Co-Director Kristin M. Leiferman, MD - Co-Director Mazdak Khalighi, MD Melanie K. Kuechle, MD

417 S. Wakara Way, Suite 2151 Salt Lake City, UT 84108

Phone: 1-801-581-7139 or 1-866-266-5699 Fax: 1-801-585-5695

IMMUNODERMATOLOGY LABORATORY REPORT

Submitter

ARUP Sendouts

Pemphigoid Antibody Panel (Final result)

TESTING REPORT follows "See Note" See Note

CLINICAL INFORMATION Tense blisters on urticarial base with pruritus. Presumptive diagnosis is bullous pemphigoid.

Specimen Details - ; Collected: 3/19/2024; Received: 3/22/2024

DIAGNOSTIC INTERPRETATION

Pemphigoid Antibody Panel monitoring, positive findings supporting the diagnosis of pemphigoid

(See Results, Comments, and Previous and Current Test Results Summary Chart with Graph of ELISA results in the Enhanced Electronic Report/EELR and/or available upon request)

RESULTS Indirect Immunofluorescence (IIF) Basement Membrane Zone (BMZ) IgG, IgG4, and IgA Antibodies IgG: Negative, monkey esophagus substrate Negative, human split skin substrate

Copy For: IP18855 Printed: 3/22/2024 1:29 PM Page: 1 of 8

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 24-079-103960

Chart continues on following page(s) ARUP Enhanced Reporting | March 22, 2024 | page 2 of 9

PCP: Unspecified

- IgA: Negative, monkey esophagus substrate Negative, human split skin substrate

Reference Range: Negative - Titer less than 1:10 Borderline - Titer 1:10 Positive (H) - Titer greater than 1:10

Localization Pattern on Human BMZ Split Skin: Epidermal (roof) or combined epidermal-dermal (roof and floor) IgG and/or IgG4 BMZ antibodies = pemphigoid (including pemphigoid gestationis, bullous pemphigoid, some types of mucous membrane pemphigoid)

Dermal (floor) IgG and/or IgG4 BMZ antibodies = epidermolysis bullosa acquisita or bullous lupus erythematosus or anti-laminin-332 pemphigoid or anti-p200 (laminin gamma-1) pemphigoid or another rare pemphigoid subtype

Epidermal (roof), combined epidermal-dermal (roof and floor), or dermal (floor) IgA BMZ antibodies = linear IgA disease (including linear IgA bullous dermatosis and chronic bullous disease of childhood)

IgA and IgG basement membrane zone antibodies may be co-expressed in basement membrane zone antibody-associated diseases

```
(H) = high/positive
```

Enzyme-Linked Immunosorbent Assay (ELISA)

Bullous Pemphigoid (BP)180 and BP230 IgG Antibodies

IgG BP180 antibody level: 49 U/mL (H)

Reference Range: Normal (negative) = Less than 9 U/mL Increased (H) (positive) = 9 U/mL and greater

IgG BP230 antibody level: 3 U/mL

Copy For: IP18855 Printed: 3/22/2024 1:29 PM Page: 2 of 8



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 24-079-103960

Chart continues on following page(s) ARUP Enhanced Reporting | March 22, 2024 | page 3 of 9

PCP: Unspecified

```
Reference Range:
                Normal (negative) = Less than 9 U/mL
Increased (H) (positive) = 9 U/mL and greater
(H) = high/positive
U = semiquantitative antibody level in ELISA units
```

COMMENTS

Specific

The positive IgG4 basement membrane zone antibody reactivity demonstrating epidermal localization (roof) with split skin substrate, also known as salt split skin, by indirect immunofluorescence and the increased IgG BP180 antibody level by ELISA, provide support for the diagnosis of pemphigoid. Previous testing showed findings supporting the diagnosis of pemphigoid and also a normal IgG type VII collagen antibody level by ELISA on one determination. Although IgA basement membrane zone antibodies can be co-expressed with IgG antibodies, no positive IgA basement membrane zone antibody reactivity is detected by indirect immunofluorescence in current or previous testing to indicate this or to support a diagnosis of linear IgA disease or linear IgA/IgG bullous dermatosis. See chart (below) for summary of previous and current basement membrane zone antibody test results; a graph of the ELISA results is available in the Enhanced Electronic Report/EELR and/or available upon request by contacting ARUP Client Services at 1-800-242-2787, option 2, and ask to speak with the Immunodermatology Laboratory at the University of Utah regarding patient results.

Detection, levels, and patterns of diagnostic antibodies may fluctuate with disease manifestations, and IgG BP180 antibody levels correlate with disease activity in some patients with pemphigoid. Clinical correlation is needed, including treatment status, with consideration for continued monitoring of serum antibody profiles by indirect immunofluorescence and antibody levels by ELISAs to aid in assessing disease expression and activity, including response to therapy.

General

Approximately 80 percent of patients with bullous pemphigoid, epidermolysis bullosa acquisita, and linear IgA bullous dermatosis have positive antibodies to basement membrane zone components in their sera detected by indirect immunofluorescence. Approximately 50 percent of patients with mucous membrane/cicatricial pemphigoid demonstrate antibodies to basement membrane zone components detected by indirect immunofluorescence. IgG4 subclass reactivity by indirect immunofluorescence may be more sensitive than IgG in some patients with pemphigoid and epidermolysis bullosa acquisita. The immunoglobulin class of basement membrane zone antibodies and pattern of antibody localization with split skin substrate (also known as salt split skin)

Copy For: IP18855 Printed: 3/22/2024 1:29 PM Page: 3 of 8

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 24-079-103960

Chart continues on following page(s) ARUP Enhanced Reporting | March 22, 2024 | page 4 of 9



distinguish the diseases. Positive serum IgA epithelial basement membrane zone antibodies are highly specific diagnostic markers for linear IgA disease. IgA basement membrane zone antibodies by indirect immunofluorescence may be found in variant presentations of mucous membrane pemphigoid and epidermolysis bullosa acquisita. Moreover, IgA basement membrane zone antibodies may be co-expressed with IgG basement membrane zone antibodies in some patients with pemphigoid including mucous membrane/cicatricial pemphigoid and in linear IgA/IgG bullous dermatosis.

Major molecular structures in the basement membrane zone to which IgG pemphigoid antibodies bind have been identified and termed "BP180" for a 180 kDa bullous pemphigoid antigen (also known as bullous pemphigoid antigen 2, BPAG2, or type XVII collagen, COL17) and "BP230" for a 230 kDa bullous pemphigoid antigen (also known as bullous pemphigoid antigen 1, BPAG1). BP180 is a transmembrane component of the basement membrane zone with collagen-like domains; the non-collagenous 16A (NC16A) antigenic domain of BP180 has been identified as a main antigenic target. BP230 is located in the hemidesmosomal plaque of basal cells in the epidermis. Serum levels of IgG BP180 and IgG BP230 antibodies are determined by ELISA, which may be more sensitive than indirect immunofluorescence. Serum levels of IgG BP180 antibodies may correlate with disease activity in pemphigoid, diminishing with treatment response. Up to 7 percent of individuals who do not have pemphigoid, including patients with other immunobullous diseases, have increased levels of IgG BP180 antibodies by ELISAs.

Patients with pemphigoid may show reactivity to multiple basement membrane zone components in addition to or other than the BP180 and BP230 epitopes in the tested ELISAs. Type VII collagen is a component of anchoring fibrils within epithelial basement membrane zone (skin and mucous membranes) and is an antigenic target of IqG autoantibodies in patients with epidermolysis bullosa acquisita and in a subset of patients with bullous lupus erythematosus and, potentially, as overlapping basement membrane zone antibody expression in patients with other epithelial antibody-associated disease. Tests that detect antibodies with specificity for other basement membrane zone antigens, including laminin-332, p200 (laminin gamma-1), and alpha6beta4 integrin, may be more sensitive than indirect immunofluorescence but are not currently available, except laminin-332 IgG antibodies in select laboratories. Mucous membrane involvement is predominant in antilaminin-332 pemphigoid. Recognition of the association of this pemphigoid variant with underlying or developing malignancy (typically solid tumor) in up to one third of cases is critical so appropriate clinical evaluation is conducted. Patients with anti-p200 (laminin gamma-1) pemphigoid tend to be younger than those with bullous pemphigoid and have lesions that clinically resemble both bullous pemphigoid and the inflammatory epidermolysis bullosa acquisita variant that may include mucosal involvement. For those patients with antibodies to alpha6beta4 integrin, alpha6 epitopes primarily are targeted in oral pemphigoid, and beta4 epitopes primarily are targeted in ocular pemphigoid.

Copy For: IP18855 Printed: 3/22/2024 1:29 PM Page: 4 of 8



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 24-079-103960

Chart continues on following page(s) ARUP Enhanced Reporting | March 22, 2024 | page 5 of 9 PCP: Unspecified

TESTING METHODS Indirect Immunofluorescence (IIF)

IgG, IgG4, and IgA Epithelial Basement Membrane Zone (BMZ) Antibodies

Patient serum is progressively diluted beginning at 1:5 in three twofold screening dilutions, layered on sections of human skin split at the basement membrane zone and monkey esophagus substrates, and reacted with fluorescein isothiocyanate (FITC)-conjugated antibodies to IgG and IgA. When positive, the serum is further diluted in two-fold reductions to the limiting dilution of antibody detection or to a maximum dilution of 1:40,960. The limiting-dilution, end-point titer is reported for each substrate, and the pattern of staining on split skin substrate also is reported. FITC-conjugated anti-IgG4 is tested to increase test sensitivity (maximum serum dilution of 1:20). This indirect immunofluorescence testing was developed, and its performance characteristics determined by the Immunodermatology Laboratory at the University of Utah. It has not been cleared or approved by the FDA (US Food and Drug Administration). FDA clearance or approval currently is not required for this testing performed in a CLIA-certified laboratory (Clinical Laboratory Improvement Amendments) and intended for clinical use. [Indirect immunofluorescence, three antibodies on two substrates (IIF X 6)]

Enzyme-Linked Immunosorbent Assays (ELISA)

IGG BP180 and IGG BP230 serum antibody levels determined by U.S. Food and Drug Administration (FDA)-approved ELISAs (Mesacup, MBL BION). [Two ELISAs]

TEST RESULTS SUMMARY CHART _____ Basement Membrane Zone (BMZ) Antibodies Serum Date of IgG and IgG4 IgA BP BP Col Number Specimen BMZ Titers BMZ Titers 180 230 VII 20-0001 03/26/20 IgG ME Neg ME Neg 52 4 NA IgG SS Neg SS Neg IqG4 ME 1:5 IgG4 SS Epi 1:20 20-0002 11/15/20 IgG ME Neg ME Neg 57 4 NA IgG SS Neg SS Neg IgG4 ME 1:10 IgG4 SS Epi, 1:20

Copy For: IP18855 Printed: 3/22/2024 1:29 PM Page: 5 of 8

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 24-079-103960

Chart continues on following page(s) ARUP Enhanced Reporting | March 22, 2024 | page 6 of 9

PCP: Unspecified


21-0003 01/06/21	IgG ME Neg IgG SS Epi, 1:10 IgG4 ME 1:20 IgG4 SS Epi, >1:20	ME Neg SS Neg	67	6	NA	
21-0004 05/20/21	IgG ME Neg IgG SS Epi, 1:20 IgG4 ME 1:10 IgG4 SS Epi, 1:20	ME Neg SS Neg	59	5	NA	
21-0005 07/24/21	IgG ME Neg IgG SS Epi, 1:10 IgG4 ME 1:10 IgG4 SS Epi, 1:20	ME Neg SS Neg	53	4	2	
24-2515 03/19/24	IgG ME Neg IgG SS Neg IgG4 ME 1:10 IgG4 SS Epi, 1:20	ME Neg SS Neg	49	3	NA	
ELISA Reference Ranges:						
IgG BP180 and IgG BP230 Antibody Levels Normal (negative) = Less than 9 U/mL Increased (H) (positive) = 9 U/mL and greater						
IgG Type VII Collagen Antibody Level						
Normal (negative) = Less than 7 U/mL Slightly increased (H) (positive) = 7-8 U/mL Increased (H) (positive) = 9 U/mL and greater						
Chart Key:						
IgG BMZ = IgG basement membrane zone (BMZ) antibodies						
by indirect immunofluorescence IgG4 BMZ = IgG4 basement membrane zone (BMZ) antibodies						
by indirect immunofluorescence IgA BMZ = IgA basement membrane zone (BMZ) antibodies by indirect immunofluorescence						
<pre>ME = Antibody absence (negative) or antibody presence (positive endpoint titer) on monkey esophagus (ME) substrate</pre>						
substrate SS = Antibody absence (negative) or antibody presence (positive pattern and endpoint titer) on split skin (SS) substrate						
Copy For: IP18855					Printed: 3/22/2024 1:29 PM Page: 6 of 8	

Ø 8

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: ARUP Accession: 24-079-103960

Chart continues on following page(s) ARUP Enhanced Reporting | March 22, 2024 | page 7 of 9





<pre>Epi = epidermal localization (roof) with split skin substrate (IgG - pemphigoid including bullous pemphigoid, some mucous membrane pemphigoid, and other pemphigoid variants; IgA - linear IgA disease including linear IgA bullous dermatosis and chronic bullous disease of childhood)</pre>					
<pre>Derm = dermal localization (floor) with split skin substrate (IgG - epidermolysis bullosa acquisita, bullous lupus erythematosus, anti-laminin-332 pemphigoid, anti-p200 (laminin gamma-1) pemphigoid, other rare pemphigoid subtypes; IgA - linear IgA disease including linear IgA epidermolysis bullosa acquisita) Comb = combined epidermal-dermal localization (roof and floor) with split skin substrate (IgG - pemphigoid and pemphigoid variants; IgA - linear IgA disease)</pre>					
BP180 = IgG BP180 antibody level (U/mL) by ELISA BP230 = IgG BP230 antibody level (U/mL) by ELISA Col VII = IgG Collagen VII antibody level (U/mL) by ELISA					
Neg = Negative NA = Not Assayed					
Electronically signed by One 03/22/24 at 1:23 PM.					
ELISA RESULTS GRAPH (may be found on next page)					

Copy For: IP18855 Printed: 3/22/2024 1:29 PM Page: 7 of 8

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 24-079-103960

Chart continues on following page(s) ARUP Enhanced Reporting | March 22, 2024 | page 8 of 9





Resulting Laboratory IMMUNODERMATOLOGY LABORATORY University of Utah 417 S. Wakara Way, Suite 2151 Salt Lake City, UT 84108 Director: Kristin M. Leiferman, MD

801-581-7139

Copy For: IP18855 Printed: 3/22/2024 1:29 PM Page: 8 of 8



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 24-079-103960

END OF CHART ARUP Enhanced Reporting | March 22, 2024 | page 9 of 9